Answer
Mepolizumab, an IgG1 kappa IL-5 antagonist, binds IL-5 with a dissociation constant of 100 pM, inhibiting its bioactivity by blocking its binding to the IL-5R alpha complex on the cell surface.
Sources for this answer
- Nucala 100 mg solution for injection in pre-filled penGlaxoSmithKline UK · emc · SmPC §5.1 Pharmacodynamic properties · Version 11Document updated
Sources checked